Publications by authors named "Laura Antohi"
Aims: To assess the potential interaction between non-cardiac comorbidities (NCCs) and the efficacy and safety of high-intensity care (HIC) versus usual care (UC) in the STRONG-HF trial, including stable patients with improved but still elevated natriuretic peptides.
Methods And Results: In the trial, eight NCCs were reported: anaemia, diabetes, renal dysfunction, severe liver disease, chronic obstructive pulmonary disease/asthma, stroke/transient ischaemic attack, psychiatric/neurological disorders, and malignancies. Patients were classified by NCC number (0, 1, 2 and ≥3).
Article Synopsis
- * Treatment often involves diuretic therapy, with options for intravenous or increased oral doses, and the use of guideline-recommended medical therapy (GRMT) is also emphasized.
- * Early prevention and management, including outpatient care and rapid initiation of GRMT, are crucial in reducing the frequency of worsening HF episodes, as highlighted in the consensus statement by the Heart Failure Association of the European Society of Cardiology.
The coronavirus 2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF). Several consensus documents describe the appropriate diagnostic algorithm and treatment approach for patients with HF and associated COVID-19 infection. However, few questions about the mechanisms by which COVID can exacerbate HF in patients with high-risk (Stage B) or symptomatic HF (Stage C) remain unanswered.
View Article and Find Full Text PDF